Synonym
Elarofiban; RWJ-53308; RWJ 53308; RWJ53308.
IUPAC/Chemical Name
(S)-beta-((R)-1-(3-(4-Piperidyl)propionyl)nipecotamido)-3-pyridinepropionic acid
InChi Key
ABNXKGFLZFSILK-MOPGFXCFSA-N
InChi Code
InChI=1S/C22H32N4O4/c27-20(6-5-16-7-10-23-11-8-16)26-12-2-4-18(15-26)22(30)25-19(13-21(28)29)17-3-1-9-24-14-17/h1,3,9,14,16,18-19,23H,2,4-8,10-13,15H2,(H,25,30)(H,28,29)/t18-,19+/m1/s1
SMILES Code
O=C(O)C[C@H](NC([C@@H]1CCCN(C(CCC2CCNCC2)=O)C1)=O)C3=CC=CN=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
416.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ.
Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal
absorption analysis. J Pharmacol Toxicol Methods. 2001 Jul-Aug;46(1):51-5. PubMed
PMID: 12164260.
2: Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haertlein BJ, de Garavilla L,
Kauffman JA, Hoekstra WJ, Maryanoff BE, Andrade-Gordon P. Antiplatelet and
antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa
antagonist. Thromb Res. 2001 Oct 15;104(2):113-26. PubMed PMID: 11672755.
3: Lawson EC, Hoekstra WJ, Addo MF, Andrade-Gordon P, Damiano BP, Kauffman JA,
Mitchell JA, Maryanoff BE. 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained
template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett.
2001 Oct 8;11(19):2619-22. PubMed PMID: 11551763.
4: Hoekstra WJ, Maryanoff BE, Damiano BP, Andrade-Gordon P, Cohen JH, Costanzo
MJ, Haertlein BJ, Hecker LR, Hulshizer BL, Kauffman JA, Keane P, McComsey DF,
Mitchell JA, Scott L, Shah RD, Yabut SC. Potent, orally active GPIIb/IIIa
antagonists containing a nipecotic acid subunit. Structure-activity studies
leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
PubMed PMID: 10602710.